Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials

被引：0

作者：

Gottlieb, A. B. ^{[1
]}

Thaci, D. ^{[2
]}

Leonardi, C. ^{[3
,4
]}

Poulin, Y. ^{[5
]}

Kavanagh, S. ^{[6
]}

Boehnlein, M. ^{[7
]}

Reich, K. ^{[8
,9
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Lubeck, Lubeck, Germany

[3] Cent Dermatol, St Louis, MO USA

[4] St Louis Univ, Sch Med, St Louis, MO USA

[5] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[6] UCB Pharma, Raleigh, NC USA

[7] UCB Pharma, Monheim, Germany

[8] SCIderm Res Inst, Hamburg, Germany

[9] Dermatologikum Berlin, Berlin, Germany

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷

关键词：

Certolizumab Pegol; Nail disease; Psoriasis;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P116

引用

页码：54 / 54

页数：1

共 50 条

[31] Improvements in scalp and nail psoriasis with apremilast treatment in patients with moderate to severe plaque psoriasis with and without a history of psoriatic arthritis
Crowley, Jeffrey
Gooderham, Melinda
Richter, Sven
Shi, Rebecca
Reich, Kristian
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB62 - AB62
[32] A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
Coto-Segura, Pablo
Segu-Verges, Cristina
Martorell, Antonio
Moreno-Ramirez, David
Jorba, Guillem
Junet, Valentin
Guerri, Filippo
Daura, Xavier
Oliva, Baldomero
Cara, Carlos
Suarez-Magdalena, Olaya
Abraham, Sonya
Mas, Jose Manuel
[J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
[33] BIMEKIZUMAB EFFICACY IN MODERATE TO SEVERE PLAQUE PSORIASIS: IMPROVEMENTS IN FATIGUE OBSERVED IN TWO PHASE 3 STUDIES
Gottlieb, Alice B.
Augustin, Matthias
Lambert, Jo
Pinter, Andreas
Savage, Laura J.
Tsai, Tsen-Fang
Foley, Peter
Paul, Carle
Warham, Rhys
Lambert, Jeremy
Wiegratz, Susanne
Stahle, Mona
[J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
[34] Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
Blauvelt, Andrew
Tada, Yayoi
Iversen, Lars
Mrowietz, Ulrich
Lebwohl, Mark
Wang, Maggie
Vanvoorden, Veerle
Cullen, Eva
Staelens, Fabienne
Papp, Kim A.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
[35] Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis
Papp, Kim
Crowley, Jeffrey
Paul, Carle
Gooderham, Melinda
Reich, Kristian
Hu, ChiaChi
Day, Robert M.
Griffiths, Christopher E. M.
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[36] Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Fan, Wen
Lei, Na
Zheng, Yujie
Liu, Juan
Cao, Xuechen
Su, Ting
Su, Zhonglan
Lu, Yan
[J]. SCIENTIFIC REPORTS, 2024, 14 (01):
[37] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Kaur, Mandeep
Lan, Shuping
Mallbris, Lotus
Mamolo, Carla
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
[38] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis
Kaur, M.
Merola, J.
Tatulych, S.
Mamolo, C.
Lan, S.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 81 - 81
[39] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Mamolo, Carla
Lan, Shuping
Mallbris, Lotus
Kaur, Mandeep
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[40] Patients with moderate to severe plaque psoriasis show consistently a quick improvement of nail psoriasis
Schopf, R.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 : 193 - 193

← 1 2 3 4 5 →